Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs

MELBOURNE, Australia, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel treatments for chronic diseases such as recurrent and metastatic cancer, today announced plans to investigate the phenomenon of “mesenchymal drift”—an emerging area of research that may help unlock the mechanisms behind the reversal of chronic diseases. The concept, advanced by leaders in the field including Altos Labs, Inc., aligns with Propanc’s expanding research efforts into how its lead product candidate, PRP, may influence the epithelial-to-mesenchymal transition (EMT) and related pathways central not only to cancer progression but also other chronic diseases. Fibrosis, a major cause of age-related organ failure, represents one such application. Propanc recently filed a patent application describing a PRP-based treatment method for fibrotic disease.